Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tarsus Pharmaceuticals, Inc. filings document operating results, product commercialization, pipeline disclosures, governance matters, and capital-market reporting for a Nasdaq-listed biopharmaceutical company. Form 8-K reports include quarterly and annual financial results, XDEMVY net product sales commentary, corporate presentations, and clinical or commercial business updates involving TP-04 and TP-05.
Proxy and governance filings describe board composition, committee assignments, director elections, executive compensation, auditor ratification, stockholder voting results, and related compensation policies. The filing record also includes material-event disclosures for board appointments, Regulation FD presentations, common-stock voting matters, and formal disclosure of risk, oversight, and governance subjects relevant to Tarsus' commercial-stage pharmaceutical business.
Tarsus Pharmaceuticals, Inc. (TARS) received a Rule 144 notice for a planned resale of common stock by company officer Elizabeth Yeu-Lin. The notice covers 10,773 shares of common stock, acquired in open market purchases on September 14, 2022 and August 15, 2023, with an aggregate market value of $942,635.00 as of the notice.
The filing states that Tarsus had 43,882,996 shares of common stock outstanding. It also lists sales during the past three months totaling 11,578 shares of common stock for approximately $897,989.86, including sales from the account of the officer’s spouse, which are aggregated under Rule 144.
Tarsus Pharmaceuticals, Inc. (TARS) has a notice under Rule 144 indicating that officer Seshadri Neervannan plans a potential sale of up to 4,564 shares of common stock through Fidelity Brokerage Services LLC. The planned sale relates to shares acquired via restricted stock vesting and an employee stock purchase plan in 2023.
The notice reports an aggregate market value of about $387,940 for these shares and lists 43,882,996 common shares outstanding, providing context for the size of the proposed sale.
Tarsus Pharmaceuticals, Inc. (TARS) reported that President, CEO and Board Chair Bobak R. Azamian, through the Bobak Azamian Living Trust, sold 10,000 shares of common stock on September 2, 2026 in open-market transactions at a weighted average price of $80.06 per share, with individual sale prices ranging from $80.00 to $80.20.
These sales were made under an automatic Rule 10b5-1 trading plan adopted on December 9, 2025. Following the sale, the trust held 837,991 shares of Tarsus common stock, and Azamian also held 33,421 shares directly, over which he retains voting and dispositive power in the case of the trust-held shares.
Tarsus Pharmaceuticals, Inc. (TARS) reported that Chief Medical Officer Elizabeth Yeu Lin sold a total of 11,578 shares of common stock on September 1–2, 2026, at prices between $73.86 and $80.00 per share, including indirect sales through a spouse’s Roth IRA, under Rule 10b5-1 trading plans.
Tarsus Pharmaceuticals, Inc. (TARS) is the issuer of common stock for which Elizabeth Yeu-Lin, through an account at Fidelity Brokerage Services LLC, has filed a notice of a proposed sale under Rule 144. The notice covers 1,590 shares of common stock with an aggregate market value of $127,200.00, based on 43,882,996 shares outstanding as of September 2, 2026 on NASDAQ. A related person, identified in the remarks as spouse Stephen Lin, previously sold 4,601 shares of Tarsus common stock for $339,829.86 on September 1, 2026.
Tarsus Pharmaceuticals, Inc. (TARS) has a notice under Rule 144 for a planned sale of common stock by former officer Aziz A. Mottiwala through Fidelity Brokerage Services LLC. The notice covers 8,000 shares of common stock, to be sold following a stock option exercise on July 27, 2020, for cash.
The notice states that 43,882,996 shares of Tarsus common stock were outstanding as of September 2, 2026. It also lists prior Rule 144 sales by Aziz A. Mottiwala in the past three months, including 53,043 shares on August 19, 2026, 81,332 shares on August 25, 2026, and 77,698 shares on September 1, 2026, with corresponding aggregate sale amounts disclosed.
Tarsus Pharmaceuticals, Inc. (TARS) has a notice of proposed sale of common stock filed for the account of officer Elizabeth Yeu-Lin under Rule 144. The filing lists a proposed sale of 5,387 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $430,960.00, based on a market for the shares on NASDAQ as of September 2, 2026. Shares of Tarsus Pharmaceuticals, Inc. outstanding are stated as 43,882,996 as of that date; this is a baseline figure, not the amount being sold.
The notice also reports that during the past three months, 4,601 shares of Tarsus common stock were sold on September 1, 2026 for $339,829.86. Earlier acquisitions of the securities to be sold include open market purchases of 2,377 shares on August 15, 2023 and 3,010 shares on September 14, 2022.
Tarsus Pharmaceuticals, Inc. (TARS) received a notice that officer Bobak Azamian, through the Bobak Azamian Living Trust, intends to sell 10,000 shares of common stock under Rule 144, with an indicated aggregate market value of $800,568.71, through Merrill Lynch on NASDAQ.
The shares to be sold were originally acquired on January 13, 2017 in a private placement. In the preceding three months, the Bobak Azamian Living Trust sold an additional 10,000 shares of Tarsus common stock on June 17, 2026 for proceeds of $615,473.27.
Tarsus Pharmaceuticals, Inc. (TARS) is the issuer for a Form 144 filed for the account of former officer Aziz A. Mottiwala. The notice covers a proposed sale of up to 77,698 shares of common stock, planned in connection with a stock option exercise dated September 1, 2026. The securities are to be sold through Fidelity Brokerage Services LLC, with trading on NASDAQ. The filing also lists prior sales of common stock by Aziz A. Mottiwala during the past three months.
Tarsus Pharmaceuticals, Inc. (TARS) has a planned sale of common stock under Rule 144 by officer Elizabeth Yeu-Lin through Fidelity Brokerage Services LLC. The notice covers 4,601 shares of common stock, tied to an aggregate value of $339,829.86, with Tarsus having 43,882,996 shares outstanding and an approximate sale date of September 1, 2026.
The securities relate to restricted stock that vested on June 16, 2023 (2,000 shares) and June 22, 2024 (2,601 shares), both characterized as compensation from the issuer.